Analysts’ Viewpoint on Chronic Kidney Disease Nutritional Supplement Market Scenario
Patients use nutritional supplements for the treatment of chronic kidney disease, which has been recognized as a leading public health issue across the globe. Availability of medical foods and increase in consideration of these products to manage and control chronic kidney disease (CKD) are expected to propel the global market. Rise in development of new foods for special medical purposes is also likely to augment the global market. Rapid digitization has resulted in strong penetration of e-commerce in countries in Asia Pacific, with China accounting for a large chronic kidney disease nutritional supplement market share. Several governments and private companies across the world are promoting dietary supplements to control and prevent diseases, and reduce the prevalence of health conditions. This is likely to drive the global chronic kidney disease nutritional supplement market size. Market players should continue investing in research & development activities and innovation in chronic kidney disease nutritional supplement products to broaden their revenue streams.
Nutrition plays a vital role in chronic kidney disease (CKD) outcomes. The correlation between nutrition and chronic kidney disease is evident in many cases; dietary supplements helps facilitate patient recovery. For instance, micronutrients such as sodium and phosphorus are vital ingredients of dietary supplements and are being increasingly preferred over chronic kidney disease (CKD) drugs. Nutrition for advanced chronic kidney disease includes amino acid supplements, vitamin & mineral supplements, probiotics, prebiotics/fibers, and herbal supplements. A person may prevent or delay some health issues from chronic kidney disease by choosing the right foods and avoiding foods high in sodium, potassium, and phosphorus.
Increase in geriatric population, rise in prevalence of chronic kidney disease (CKD), surge in usage of medical food supplements for chronic renal failure, and growth in sales through e-commerce platforms are the major factors propelling the global market. Geriatric population is increasing across the globe. This population is more prone to chronic diseases such as chronic kidney disease. According to the United Nations World Population Ageing 2019 report, 703 million people were aged 65 years or above globally in 2019, which is projected to double to reach 1.5 billion by 2050. According to recent estimates from researchers at the Johns Hopkins University, more than 50% of individuals over the age of 75 are believed to have kidney disease. Kidney disease has also been found to be more prevalent in those over the age of 60 compared to the rest of the general population.
According to Centers for Disease Control and Prevention (CDC) estimates published in March 2021, CKD is more common in individuals aged 65 years or older (38%) than in people aged 45–64 years (12%) or 18–44 years (6%). CKD is slightly more common in women (14%) than men (12%). The CDC stated that more than one in 7 (15%) of the U.S. adults, or 37 million patients, are estimated to have CKD currently.
The global estimated prevalence of CKD is 13.4% (11.7%–15.1%), and patients with end-stage kidney disease (ESKD) needing renal replacement therapy is estimated between 4.90 million and 7.08 million. In 2017, the global prevalence of CKD stood at 9.1% or about 700 million cases. CKD is a major public health issue in low- and middle-income countries (LMICs). Its prevalence has been increasing rapidly in these countries, particularly in countries in Asia.
The chronic kidney disease population utilizes nutritional supplements for CKD treatment. According to the Mayo Clinic researchers (September 2019), more than one-third of the 15.7 million (~5.3 billion) Americans with moderate or advanced CKD use dietary or herbal supplements.
The Orphan Drug Act defined medical food as the food that is formulated to be consumed or administered by enteral route under the supervision of a physician, and which is intended for a specific diet. Manufacturers are marketing an array of medical foods, ranging from powders and capsules for chronic kidney disease treatment. Nestlé has been pivoting to carve a niche in the medical food business and home in on personal nutrition. In August 2019, Nestlé Health Science, a wholly owned subsidiary of Nestlé S.A., acquired Persona Nutrition (formerly Vitamin Packs, Inc.) in order to gain a foothold in the personal nutrition segment. Personal nutrition includes dietary supplements, wellness products, nutraceuticals, and functional foods that help aid overall well-being or performance.
COVID-19 has had a positive effect on the global chronic kidney disease nutritional supplement size. The unprecedented outbreak of the COVID-19 pandemic has largely affected countries in North America and Europe such as the U.S., Italy, Spain, the U.K., France, and Germany. The dietary supplement industry is concentrated in these regions. The industry has benefited from the pandemic situation, as the market witnessed a surge in demand for immunity-boosting supplements. Immunity-boosting vitamins, minerals, and herbs witnessed a rise in demand in 2020, which is expected to continue till the COVID-19 vaccine reaches everyone. The spread of the COVID-19 has attracted more customer traffic to comprehensive e-commerce platforms, resulting in the easy availability of various supplement brands for consumers. Online purchasing habits of consumers developed during the pandemic are expected to continue over the next few years as well.
In terms of nutrition type, the vitamin & mineral supplements segment held the largest share of the global chronic kidney disease nutritional supplement market in 2021. Rise in need for water soluble vitamins (vitamin B, C & D) for CKD patients is propelling the segment. Vitamin C could be suggested in low dosages; large doses can cause a buildup of oxalate. B complex vitamins, iron, vitamin C, vitamin D, calcium, and phosphate are used in supplements consumed by CKD patients. Minerals, including calcium and phosphate, are consumed to help maintain bones.
The amino acid supplements segment is likely to witness significant growth during the forecast period. Alpha ketoanalogue (α-ketoanalogue) is commonly used as nutrition therapy or dietary supplement in patients with chronic kidney disease. It slows down the progression of kidney disease, improves the quality of life, and enhances calcium and phosphate metabolism.
In terms of dosage form, the capsule segment held the largest share of the global chronic kidney disease nutritional supplement market in 2021. The trend is anticipated to continue during the forecast period. This can be ascribed to the rise in acceptance of capsules over other dosage forms, as they are easier to swallow, convenient, and have a higher perceived efficiency as well as higher availability in the market.
Based on FSMP mode of administration, the enteral nutrition segment is anticipated to grow at a faster CAGR from 2022 to 2031. Enteral nutrition with foods for special medical purposes (FSMP) is recommended for most patients on home enteral nutrition. Several studies have demonstrated that enteral nutrition can provide clinical benefits at lower healthcare costs by reducing the length of hospital stays.
In terms of CKD stage, the end-stage renal disease segment accounted for significant share of the global chronic kidney disease nutritional supplement market in 2021. This can be ascribed to the increase in number of patients suffering from severe kidney failure, rapid rise in number of hospitals & urgent care centers, and surge in hospital admission rates. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 786,000 people in the U.S. are living with end stage kidney disease (ESKD), also known as end-stage renal disease (ESRD).
Based on distribution channel, the hospital pharmacies segment accounted for the largest share of the global chronic kidney disease nutritional supplement market in 2021. This can be ascribed to the increase in number of hospital pharmacies, rise in hospital admissions, developing healthcare infrastructure, and surge in usage of CKD nutritional supplements in dialysis patients. Currently, the U.S. has 28,738 pharmacies and drug stores, an increase of 1.7% from that in 2021. According to statistics published by the American Hospital Association (AHA), the country has 6,093 hospitals. This represents a strong base of hospital pharmacies in the country, which contributes to regional growth.
North America accounted for the largest share of the global chronic kidney disease nutritional supplement market in 2021. The trend is expected to continue during the forecast period. Growth of the market in the region can be ascribed to the presence of leading players, favorable reimbursement policies, and well-established healthcare infrastructure.
Asia Pacific is likely to capture the largest share of the global market during the forecast period due to surge in geriatric population, larger CKD patient population base, developing healthcare infrastructure, and increase in incidence of diabetes. Rise in interest of key international companies in expanding their production bases and product portfolio in countries in Asia and Southeast Asia such as South Korea, Malaysia, India, and China due to high population density is expected to propel the market in the region during the forecast period. According to the United Nations Population Fund (UNFPA), one in four people in Asia and the Pacific will be above 60 years old by 2050. The population of older persons (aged more than 60) in the region will triple between 2010 and 2050, reaching close to 1.3 billion.
The report concludes with the company profiles section that includes key information about the major players in the global chronic kidney disease nutritional supplement market. Market participants focus on strategies such as new product launches, mergers & acquisitions (M&As), and public & private partnerships to strengthen their position. Abbott Laboratories, Ajanta Pharma Limited, Fresenius Kabi AG, Hexagon Nutrition Limited, Mankind Pharma Ltd., Nestlé S.A., Nutricia Limited (Danone S.A.), PRINE Health MSO, LLC, and RPG Life Sciences Limited are the prominent players operating in the global market.
Each of these players has been profiled in the chronic kidney disease nutritional supplement market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 3.3 Bn |
|
Market Forecast Value in 2031 |
More than US$ 5.0 Bn |
|
Compound Annual Growth Rate (CAGR) |
4.3% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global chronic kidney disease nutritional supplement market was valued at US$ 3.3 Bn in 2021
The global chronic kidney disease nutritional supplement market is projected to reach more than US$ 5.0 Bn by 2031
The global chronic kidney disease nutritional supplement market is anticipated to grow at a CAGR of 4.3% from 2022 to 2031
Increase in geriatric population, rise in prevalence of chronic kidney disease, surge in usage of medical food supplements for chronic renal failure, and increase in sales through e-commerce platforms
The vitamin & mineral supplements segment accounted for around 42% share of the global chronic kidney disease nutritional supplement market in 2021
North America is expected to account for major share of the global chronic kidney disease nutritional supplement market during the forecast period
Abbott Laboratories, Ajanta Pharma Limited, Fresenius Kabi AG, Hexagon Nutrition Limited, Mankind Pharma Ltd., Nestlé S.A., Nutricia Limited (Danone S.A.), PRINE Health MSO, LLC, and RPG Life Sciences Limited
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Kidney Disease Nutritional Supplement Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Average Pricing Per Nutrition Type
5.2. Porter’s Five Force Analysis
5.3. COVID-19 Impact Analysis
5.4. Prevalence of Chronic Kidney Diseases Globally
6. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Nutrition Type, 2017–2031
6.3.1. Amino Acid Supplements
6.3.1.1. Alpha-Ketoanalogue Supplements
6.3.1.2. Alpha Lipoic Acid Supplements
6.3.1.3. Others
6.3.2. Vitamin & Mineral Supplements
6.3.3. Probiotics
6.3.4. Prebiotics/Fibers
6.3.5. Others
6.4. Market Attractiveness Analysis, by Nutrition Type
7. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Dosage Form, 2017–2031
7.3.1. Capsule Form
7.3.2. Liquid Form
7.3.3. Powder Form
7.3.4. Others
7.4. Market Attractiveness Analysis, by Dosage Form
8. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
8.3.1. Oral Nutrition (ON)
8.3.2. Enteral Nutrition (EN)
8.4. Market Attractiveness Analysis, by FSMP Mode of Administration
9. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by CKD Stage, 2017–2031
9.3.1. Pre-dialysis Stage 1-2
9.3.2. Pre-dialysis Stage 3-5
9.3.3. Dialysis
9.3.4. End-stage Renal Disease
9.4. Market Attractiveness Analysis, by CKD Stage
10. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Stores
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Nutrition Type, 2017–2031
12.2.1. Amino Acid Supplements
12.2.1.1. Alpha-Ketoanalogue Supplements
12.2.1.2. Alpha Lipoic Acid Supplements
12.2.1.3. Others
12.2.2. Vitamin & Mineral Supplements
12.2.3. Probiotics
12.2.4. Prebiotics/Fibers
12.2.5. Others
12.3. Market Value Forecast, by Dosage Form, 2017–2031
12.3.1. Capsule Form
12.3.2. Liquid Form
12.3.3. Powder Form
12.3.4. Others
12.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
12.4.1. Oral Nutrition (ON)
12.4.2. Enteral Nutrition (EN)
12.5. Market Value Forecast, by CKD Stage, 2017–2031
12.5.1. Pre-dialysis Stage 1-2
12.5.2. Pre-dialysis Stage 3-5
12.5.3. Dialysis
12.5.4. End-stage Renal Disease
12.6. Market Value Forecast, by Distribution Channel, 2017–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Stores
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Nutrition Type
12.8.2. By Dosage Form
12.8.3. By FSMP Mode of Administration
12.8.4. By CKD stage
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Nutrition Type, 2017–2031
13.2.1. Amino Acid Supplements
13.2.1.1. Alpha-Ketoanalogue Supplements
13.2.1.2. Alpha Lipoic Acid Supplements
13.2.1.3. Others
13.2.2. Vitamin & Mineral Supplements
13.2.3. Probiotics
13.2.4. Prebiotics/Fibers
13.2.5. Others
13.3. Market Value Forecast, by Dosage Form, 2017–2031
13.3.1. Capsule Form
13.3.2. Liquid Form
13.3.3. Powder Form
13.3.4. Others
13.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
13.4.1. Oral Nutrition (ON)
13.4.2. Enteral Nutrition (EN)
13.5. Market Value Forecast, by CKD Stage, 2017–2031
13.5.1. Pre-dialysis Stage 1-2
13.5.2. Pre-dialysis Stage 3-5
13.5.3. Dialysis
13.5.4. End-stage Renal Disease
13.6. Market Value Forecast, by Distribution Channel, 2017–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Stores
13.7. Market Value Forecast By Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Nutrition Type
13.8.2. By Dosage Form
13.8.3. By FSMP Mode of Administration
13.8.4. By CKD stage
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Nutrition Type, 2017–2031
14.2.1. Amino Acid Supplements
14.2.1.1. Alpha-Ketoanalogue Supplements
14.2.1.2. Alpha Lipoic Acid Supplements
14.2.1.3. Others
14.2.2. Vitamin & Mineral Supplements
14.2.3. Probiotics
14.2.4. Prebiotics/Fibers
14.2.5. Others
14.3. Market Value Forecast, by Dosage Form, 2017–2031
14.3.1. Capsule Form
14.3.2. Liquid Form
14.3.3. Powder Form
14.3.4. Others
14.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
14.4.1. Oral Nutrition (ON)
14.4.2. Enteral Nutrition (EN)
14.5. Market Value Forecast, by CKD Stage, 2017–2031
14.5.1. Pre-dialysis Stage 1-2
14.5.2. Pre-dialysis Stage 3-5
14.5.3. Dialysis
14.5.4. End-stage Renal Disease
14.6. Market Value Forecast, by Distribution Channel, 2017–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Stores
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Taiwan
14.7.5. Australia & New Zealand
14.7.6. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Nutrition Type
14.8.2. By Dosage Form
14.8.3. By FSMP Mode of Administration
14.8.4. By CKD stage
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Nutrition Type, 2017–2031
15.2.1. Amino Acid Supplements
15.2.1.1. Alpha-Ketoanalogue Supplements
15.2.1.2. Alpha Lipoic Acid Supplements
15.2.1.3. Others
15.2.2. Vitamin & Mineral Supplements
15.2.3. Probiotics
15.2.4. Prebiotics/Fibers
15.2.5. Others
15.3. Market Value Forecast, by Dosage Form, 2017–2031
15.3.1. Capsule Form
15.3.2. Liquid Form
15.3.3. Powder Form
15.3.4. Others
15.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
15.4.1. Oral Nutrition (ON)
15.4.2. Enteral Nutrition (EN)
15.5. Market Value Forecast, by CKD Stage, 2017–2031
15.5.1. Pre-dialysis Stage 1-2
15.5.2. Pre-dialysis Stage 3-5
15.5.3. Dialysis
15.5.4. End-stage Renal Disease
15.6. Market Value Forecast, by Distribution Channel, 2017–2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Stores
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Nutrition Type
15.8.2. By Dosage Form
15.8.3. By FSMP Mode of Administration
15.8.4. By CKD stage
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Nutrition Type, 2017–2031
16.2.1. Amino Acid Supplements
16.2.1.1. Alpha-Ketoanalogue Supplements
16.2.1.2. Alpha Lipoic Acid Supplements
16.2.1.3. Others
16.2.2. Vitamin & Mineral Supplements
16.2.3. Probiotics
16.2.4. Prebiotics/Fibers
16.2.5. Others
16.3. Market Value Forecast, by Dosage Form, 2017–2031
16.3.1. Capsule Form
16.3.2. Liquid Form
16.3.3. Powder Form
16.3.4. Others
16.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
16.4.1. Oral Nutrition (ON)
16.4.2. Enteral Nutrition (EN)
16.5. Market Value Forecast, by CKD Stage, 2017–2031
16.5.1. Pre-dialysis Stage 1-2
16.5.2. Pre-dialysis Stage 3-5
16.5.3. Dialysis
16.5.4. End-stage Renal Disease
16.6. Market Value Forecast, by Distribution Channel, 2017–2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Stores
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Nutrition Type
16.8.2. By Dosage Form
16.8.3. By FSMP Mode of Administration
16.8.4. By CKD stage
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2021
17.3. Company Profiles
17.3.1. Abbott Laboratories
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. Strategic Overview
17.3.1.5. SWOT Analysis
17.3.2. Ajanta Pharma Limited
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. Strategic Overview
17.3.2.5. SWOT Analysis
17.3.3. Fresenius Kabi AG
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. Strategic Overview
17.3.3.5. SWOT Analysis
17.3.4. Hexagon Nutrition Limited
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.5. Mankind Pharma Ltd.
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Strategic Overview
17.3.5.4. SWOT Analysis
17.3.6. Nestlé S.A.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. Strategic Overview
17.3.6.5. SWOT Analysis
17.3.7. Nutricia Limited (Danone S.A.)
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. Strategic Overview
17.3.7.5. SWOT Analysis
17.3.8. PRINE Health MSO, LLC
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. SWOT Analysis
17.3.9. RPG Life Sciences Limited
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. Strategic Overview
17.3.9.5. SWOT Analysis
List of Tables
Table 01: Average Pricing Per Nutrition Type
Table 02: Average Pricing Per Nutrition Type
Table 03: Prevalence of Chronic Kidney Diseases Globally
Table 04: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 05: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 06: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form , 2017–2031
Table 07: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 08: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 09: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 11: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 12: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 13: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 14: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 15: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 16: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 18: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 19: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 20: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 21: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 22: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 23: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 25: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 26: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 27: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 28: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 29: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 30: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 31: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 33: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 34: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form , 2017–2031
Table 35: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 36: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 37: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 38: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 39: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 40: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 41: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form , 2017–2031
Table 42: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 43: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 44: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 45: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Chronic Kidney Disease Nutritional Supplement (CKD) Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type, 2021 and 2031
Figure 03: Global Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Nutrition Type, 2022–2031
Figure 04: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Amino Acid Supplements, 2017–2031
Figure 05: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Vitamin & Mineral Supplements, 2017-2031
Figure 06: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Probiotics, 2017-2031
Figure 07: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Prebiotics/Fibers, 2017-2031
Figure 08: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Others, 2017-2031
Figure 09: Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form 2021 and 2031
Figure 10: Global Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 11: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Capsule Form, 2017–2031
Figure 12: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Liquid Form, 2017-2031
Figure 13: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Powder Form, 2017–2031
Figure 14: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Others, 2017-2031
Figure 15: Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration, 2021 and 2031
Figure 16: Global Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by FSMP Mode of Administration, 2022–2031
Figure 17: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Oral Nutrition, 2017–2031
Figure 18: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Enteral Nutrition, 2017-2031
Figure 19: Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage, 2021 and 2031
Figure 20: Global Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by CKD Stage, 2022–2031
Figure 21: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Pre-dialysis Stage 1-2, 2017–2031
Figure 22: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Pre-dialysis Stage 3-5, 2017-2031
Figure 23: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Dialysis, 2017–2031
Figure 24: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by End-stage Renal Disease, 2017-2031
Figure 25: Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 26: Global Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 27: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 28: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 29: Global Chronic Kidney Disease Nutritional Supplement Market (US$ Mn), by Online Stores, 2017-2031
Figure 30: Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Region, 2021 and 2031
Figure 31: Global Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Region, 2022–2031
Figure 32: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, 2017–2031
Figure 33: North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type, 2021 and 2031
Figure 34: North America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Nutrition Type, 2022–2031
Figure 35: North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form, 2021 and 2031
Figure 36: North America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 37: North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration, 2021 and 2031
Figure 38: North America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by FSMP Mode of Administration, 2022–2031
Figure 39: North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage, 2021 and 2031
Figure 40: North America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by CKD Stage, 2022–2031
Figure 41: North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 42: North America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 43: North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Country, 2021 and 2031
Figure 44: North America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Country, 2022–2031
Figure 45: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type, 2021 and 2031
Figure 47: Europe Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Nutrition Type, 2022–2031
Figure 48: Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form. 2021 and 2031
Figure 49: Europe Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 50: Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration, 2021 and 2031
Figure 51: Europe Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by FSMP Mode of Administration, 2022–2031
Figure 52: Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage, 2021 and 2031
Figure 53: Europe Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by CKD Stage, 2022–2031
Figure 54: Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 55: Europe Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 56: Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 57: Europe Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 58: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, 2017–2031
Figure 59: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type, 2021 and 2031
Figure 60: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Nutrition Type, 2022–2031
Figure 61: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form 2021 and 2031
Figure 62: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 63: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration, 2021 and 2031
Figure 64: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by FSMP Mode of Administration, 2022–2031
Figure 65: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage, 2021 and 2031
Figure 66: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by CKD Stage, 2022–2031
Figure 67: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 68: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 69: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 70: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 71: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, 2017–2031
Figure 72: Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type, 2021 and 2031
Figure 73: Latin America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Nutrition Type, 2022–2031
Figure 74: Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form, 2021 and 2031
Figure 75: Latin America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 76: Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration, 2021 and 2031
Figure 77: Latin America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by FSMP Mode of Administration, 2022–2031
Figure 78: Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage, 2021 and 2031
Figure 79: Latin America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by CKD Stage, 2022–2031
Figure 80: Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 81: Latin America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 82: Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 83: Latin America Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 84: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, 2017–2031
Figure 85: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type, 2021 and 2031
Figure 86: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Nutrition Type, 2022–2031
Figure 87: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form, 2021 and 2031
Figure 88: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 89: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration, 2021 and 2031
Figure 90: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by FSMP Mode of Administration, 2022–2031
Figure 91: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage, 2021 and 2031
Figure 92: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by CKD Stage, 2022–2031
Figure 93: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 94: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 95: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 96: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 97: Global Chronic Kidney Disease Nutritional Supplement Market Share Analysis/Ranking, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Chronic Kidney Disease [CKD] Nutritional Supplement Market
